Esomeprazole Magnesium Capsule, Delayed Release
Product Images NDC 68071-3735

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 68071-3735). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3735 6)

Esomeprazole Magnesium 20 mg delayed-release capsules label by NuCare Pharmaceuticals, Inc. The label indicates a quantity of 60 capsules. Capsules are described as oblong light blue caps with dark blue bodies, imprinted with 'RDY' and '492'. Manufactured by Dr. Reddy's Laboratories Limited, India, and packaged by NuCare Pharmaceuticals. The label includes barcode, lot, expiration, and instructions to store at controlled temperature 68-77°F with warnings to keep out of reach of children.*

FDA Label Image

Figure1 (Figure1)

Chemical structure of Esomeprazole Magnesium showing its molecular components including aromatic rings, methoxy groups, sulfoxide group, and associated magnesium ion with water molecules.*

FDA Label Image

Figure2 (Figure2)

A line graph showing the percentage of subjects maintained over 6 months for Esomeprazole at doses of 40 mg, 20 mg, and 10 mg compared to placebo. The vertical axis indicates percent maintained, and the horizontal axis shows time in months. Multiple lines represent different doses and placebo performance over time.*

FDA Label Image

Figure3 (Figure3)

A line graph depicting the percent of maximum maintenance over a 6-month period for different dosages of esomeprazole (10 mg, 20 mg, 40 mg) and placebo. The x-axis represents months from 1 to 6, and the y-axis indicates percent maintenance from 0 to 100. The graph compares the effectiveness of varying esomeprazole doses against placebo in maintaining a clinical endpoint.*

FDA Label Image

Figure4 (Figure4)

A line graph showing the percent of patients symptom-free over a 28-day period for three groups: Esomeprazole 40 mg, Esomeprazole 20 mg, and placebo. The vertical axis represents the percent symptom-free, while the horizontal axis indicates diary days from 0 to 28. The graph compares the effectiveness of two doses of Esomeprazole versus placebo over time.*

FDA Label Image

Figure5 (Figure5)

A line graph comparing the percent of patients symptom-free over 28 days among three groups: Esomeprazole 40 mg, Esomeprazole 20 mg, and placebo. The x-axis represents the diary day from 0 to 28, and the y-axis shows the percent of patients symptom-free from 0 to 100%. Three lines indicate symptom-free trends for each treatment group across the study period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.